X4 Pharmaceuticals, Inc. (XFOR)
XFORNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$3.23
+0.0800 (+2.54%) today
Pre-market, Nov 11, 4:00 PM ET
- Market cap
- $329.83m
- P/E
- –
- EPS, last 4 quarters
- $-0.6700
- Dividend yield
- –
- Day range
- –
- 52-week range
- $2.43 to $4.83
- Average volume
- –
- Previous close
- $3.15
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $11.25, +248.3% from here
Earnings
next estimate $-0.2200Next report
Dec 2025
+38.9%
Mar 2026
+20.0%
Jun 2026
+31.6%
Sep 2026
+15.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $2.57m | $2.71m | $8.81m | $2.88m |
| Gross profit | $2.20m | $2.11m | $7.19m | $2.37m |
| Operating income | -$23.70m | -$20.31m | -$16.39m | -$19.99m |
| Net income | -$23.93m | -$20.24m | -$16.16m | -$20.20m |
Last four quarters: revenue $16.96m, margin -474.7%, free cash flow –
News
8 latest- X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 4, 2026
- X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic NeutropeniaMarketBeat · Oct 29, 2026
- X4 Strengthens Cash Position Ahead Of Key Phase 3 Milestones RTTNews · Oct 8, 2026
- Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround Zacks · Sep 24, 2026
- X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks · Sep 11, 2026
- X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial RTTNews · Sep 8, 2026
- X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's WhyZacks · Aug 11, 2026
- X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 6, 2026
The company
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet medical needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is approved in the U.S. and EU as XOLREMDI for patients with WHIM syndrome. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- x4pharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.